You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Enhanced CRISPR gene editing in pluripotent stem cells using carbon nanotube arrays
SBC: Advanced Gene Transfer Company, Inc. Topic: NIGMSABSTRACT The goal of the proposed studies is to improve the efficiency of clustered regularly interspaced short palindromic repeats (CRISPR)-based gene editing in human pluripotent stem cells (PSCs), including embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs). Currently, CRISPR/Cas9 shows great potential for targeted gene editing, but remains challenging in PSCs due to their b ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Novel Combination Therapy for Treatment and Prevention of PulmonaryLymphangioleiomyomatosis (LAM) and Tuberous Sclerosis Complex (TSC)
SBC: BIOSPUTNIK LLC Topic: NHLBI1 ABSTRACT2 Tuberous sclerosis (TS), also called tuberous sclerosis complex, is a rare, multi-systemic genetic and often life-3 threatening disease that causes benign tumors to grow in the brain and on other vital organs such as the kidneys,4 heart, eyes, lungs, and skin. Lymphangioleiomyomatosis (LAM) is a TS-related tumor-like disorder. Both occur5 as a consequence of an inherited or sporadic mu ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Discovery of therapeutic nanobodies targeting brain TNF-α for the treatment of Alzheimer Disease
SBC: NANONEWRON LLC Topic: NIAProject SummarySporadic, late onset Alzheimer disease (LOAD) is the most common form of aging-dependent neurodegenerative disorder. LOAD is associated with deposition of extracellular amyloid plaques and intra-neuronal neurofibrillary tangles (NFT), formed by Aβ peptides and phosphor- tau, respectively, in the central nervous system (CNS). Although there is strong consensus that toxic forms of AΠ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
A cloud-based digital health navigation program for colorectal cancer screening
SBC: DIGITAL HEALTH NAVIGATION SOLUTIONS, INC. Topic: 102Over 30% of age-eligible Americans fail to receive recommended screening for colorectal cancer (CRC), the second leading cause of cancer death in the United States. Multilevel barriers explain why so many Americans fail to receive routine CRC screening. Patients report a lack of knowledge about the need for screening or their screening options, and many view screening as messy, uncomfortable, or e ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
MTI-301 a SCD1 inhibitor for the treatment of NASH
SBC: MODULATION THERAPEUTICS, INC. Topic: 300Abstract: Non-alcoholic fatty liver disease (NAFLD) is one of the most common liver diseases in children and adults associated with diet-associated hepatic lipid accumulation (steatosis), and is a common hepatic manifestation of obesity and metabolic syndromes including diabetes. Modulation Therapeutics is developing a stearoyl- coenzyme A desaturase-1 (SCD1) inhibitor for the treatment of NAFLD a ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
CELL EXPANSION BIOREACTORS FOR ASSAY-READY IMMUNOCOMPETENT PATIENT MODELS
SBC: Link Biosystems Inc. Topic: 102Project Summary/Abstract Although cancer is a leading cause of death globally, oncology drugs have the lowest success rates, cost the most to develop, and constantly show promising results in animals and then fail to work in patients. Thus, there is a need for models that facilitate understanding of how a drug will work in humans and for specific patient populations. The availability of human tumo ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Development of Nicotinamide-Riboside plus Pterostilbene as a Disease Modifying Osteoarthritis Therapeutic
SBC: Elysium Health, Inc. Topic: NIAMSOsteoarthritis is a progressive joint disease that affects more than 32 million Americans and over 655 million worldwide. OA is the leading cause for pain and disability in individuals over 65. Estimates place the annual US economic burden of OA at $136.4 billion. OA care continues to rely on NSAIDS for symptomatic pain management and joint replacement as a last-resort. Disease modifying OA therap ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Endoscopy-assisted intracochlear access via ultrasharp-microneedles
SBC: HAYSTACK MEDICAL, INC. Topic: NIDCDPROJECT SUMMARY / ABSTRACT Up to 2.5 billion people worldwide will suffer from hearing loss or balance disorders by 2050, with a significant portion having underlying causes in the inner ear. This includes hearing loss due to age, noise and medications as well as various balance disorders, which in total afflicts approximately one in three people between the ages of 65 and 751. Atraumatic medical ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Mosaic Display of Multivalent Tau and A-Beta peptides on Immunogenic SNAP Liposomes
SBC: POP Biotechnologies Inc. Topic: NIAProject Summary/Abstract Alzheimer’s disease (AD) currently affects ~6.2 million Americans, and this number is projected to increase to 14 million by 2060 unless novel treatments or interventions to prevent or delay the onset of AD are identified. Harnessing the immune system to prevent or remove Aβ and/or tau pathologies represents a promising disease- modifying therapeutic approach for the tr ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
An R2 non-neuroinvasive herpes simplex virus type 2 vaccine
SBC: THYREOS INC Topic: NIAIDPROJECT SUMMARY There is an unmet need for a herpes simplex virus (HSV) vaccine. We propose to develop a live-attenuated HSV-2 vaccine based on our R2 technology platform. R2 vaccines show unprecedented safety and efficacy in animal models, and offer antigenicity superior to subunit/mRNA and single-round vaccine designs. R2 vaccines are also the first live-attenuated alphaherpesvirus vaccines that ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health